Immunic, Inc. (IMUX)
Health Care · Biotechnology · NASDAQ
Immunic is a late-stage biotechnology firm developing oral, small-molecule treatments for multiple sclerosis and other neurodegenerative diseases, led by its flagship candidate, vidofludimus calcium.
What Immunic, Inc. does
Immunic is a late-stage biotechnology company focused on developing oral, small-molecule therapies for neurologic and autoimmune diseases. Its primary focus is its lead candidate, vidofludimus calcium (IMU-838), which is in late-stage clinical development for the treatment of relapsing and progressive forms of multiple sclerosis. The company also maintains a pipeline of earlier-stage programs targeting neurodegenerative and inflammatory conditions.
Recent developments
Immunic appointed Elena Ridloff to its Board of Directors in August 2026 to enhance financial and commercial leadership as it approaches Phase 3 data for its lead MS program. The company also plans to initiate a Phase 3 trial in progressive MS by the end of 2026.
From Immunic, Inc.'s filing of 2026-08-11.
Themes: multiple sclerosis, neurodegenerative diseases, autoimmune diseases, oral therapies, small molecule drugs
Fundamentals
- Price$7.41 as of 2026-10-20 close
- Market cap$101M as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return-11.4% 2025-10-20 close $8.36 → 2026-10-20 close $7.41
- P/En/a negative earnings
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.07 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How IMUX compares in its sector
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$35M | -$34M | -$0.80 | -$31M† | $249000† |
| Q1 FY2026 2026-03-31 | -$33M | -$33M | -$1.08 | -$17M | $2000 |
| Q4 FY2025 2025-12-31 | -$23M† | -$19M† | -$0.07† | -$19M† | $11000† |
| Q3 FY2025 2025-09-30 | -$26M | -$26M | -$0.13 | -$20M† | $67000† |
| Q2 FY2025 2025-06-30 | -$27M | -$27M | -$2.03 | -$25M† | $36000† |
| Q1 FY2025 2025-03-31 | -$27M | -$25M | -$2.51 | -$22M | $47000 |
| Q4 FY2024 2024-12-31 | -$26M† | -$25M† | -$0.25† | -$23M† | $3000† |
| Q3 FY2024 2024-09-30 | -$26M | -$24M | -$0.24 | -$21M† | $50000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$155M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Immunic, Inc. looks technically
Immunic, Inc. (IMUX) is trading 35.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 153 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago. It is 57.5% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 35.1% below its 200-day average, the long-term trend line — a long-term downtrend | -35.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.63 | $11.63 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.42 | $11.42 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 62 calendar days ago — the swings before that are what the structure reading is measured on | 62 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 153 trading days ago — a "golden cross", a bullish long-term signal | 153 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 42.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 34.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($6.35 to $9.47) — its "stochastic" reading is 34 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 34.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.43 | $17.43 |
|---|---|---|
| From the 52-week high | it is 57.5% below its 52-week high (its highest price of the past year) | -57.5% |
| Above the 52-week low | it is 46.4% above its 52-week low (its lowest price of the past year) | +46.4% |
| Below the 52-week high | it is 57.5% below its highest point of the past year | 57.5% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $14080.00 (set on 2014-06-13) | $14080.00 |
| Given back of the 52-week move | over the past year its closes ranged ($5.10 to $16.90), and it has given back almost all of its rise from last year’s low — 80% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.23 to $9.61. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 80.4% |
| From the all-time high | it is 99.9% below its all-time high | -100.0% |
| Nearest price level | it is trading 3.0% above a support level at $7.18 — a price it turned at twice since 2026-01-09, most recently on 2026-01-26. Since 2024-10-21 it has 2 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.0% |
| All-time low | its lowest closing price on record is $5.06 (set on 2025-12-30) | $5.06 |
| Above the all-time low | it is 46.4% above its all-time low | +46.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 74% of it) | 74th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7673 between its high and its low — about 10.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7673 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.23 and $9.93 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.23 – $8.08 – $9.93 |
| Typical daily range (% of price) | its price moves about 10.4% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.4% |
| Stretch from the 200-day average | it is trading 5.2 daily ranges below its 200-day average price (35.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 2.3% gap up opened on 2026-09-21 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 21 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +6.31% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 31.2 percentage points (the stock lost 30.2% while the market gained 1.0%) | -31.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 54.2 percentage points (the stock lost 50.6% while the market gained 3.6%) | -54.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 30.9 percentage points (the stock lost 22.4% while the market gained 8.5%) | -30.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 25.9 percentage points (the stock lost 11.4% while the market gained 14.6%) | -25.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 47% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.5% of the share price. | -46.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $10.89 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | -32.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 30% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $10.63 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -30.3% |
Price levels it has turned at before
IMUX last closed at $7.41 on 2026-10-20. Since 2024-10-21 it has turned at 2 prices below its last close and 11 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.18 | Support | 3.0% below the last close | turned there twice · 2026-01-09 to 2026-01-26 |
| $6.73 | Support | 9.1% below the last close | turned there three times · 2025-06-23 to 2025-11-20 |
| $8.31 | Resistance | 12.2% above the last close | turned there twice · 2025-04-09 to 2026-02-24 |
| $9.19 | Resistance | 24.0% above the last close | turned there three times · 2025-01-21 to 2025-06-10 |
| $9.57 | Resistance | 29.1% above the last close | turned there twice · 2025-04-30 to 2025-05-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$43.09 range $22.00 – $85.00; median $30.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMUX
- Consensus EPS estimate-$0.9618 next reporting period, as of 2026-10-16
- Estimate change, 30 days$0.00 from -$0.9618, on 2026-09-11, 35-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the success of the lead clinical candidate, vidofludimus calcium, in ongoing Phase 3 trials.","Significant risks related to the regulatory approval process and potential for clinical trial endpoints to be missed or outcomes to differ from projections.","History of losses and dependence on future capital raising to continue operations and fund late-stage development."]
What changed in the latest 10-Q
AI-assisted comparison of IMUX's 10-Q filed 2026-08-11 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Notes:
- The provided newer and older texts are truncated at the same point ('Part II,'), so only the introductory portion of the MD&A is comparable. No differences were found within the provided text.
Risk Factors
- Added:
- Newer filing (2026-08-11) adds IMU-381 to the list of product candidates described as potentially able to safely and effectively target diseases: 'the potential for vidofludimus calcium, IMU-381 and IMU-856 to safely and effectively target diseases'.
- Newer filing (2026-08-11) adds language about the timing of any new drug application submission and regulatory approval to the forward-looking statements risk factor list: 'the development, timing and commercial potential of any product candidates of the Company, including the timing of any new drug application submission and regulatory approval'.
- Newer filing (2026-08-11) adds language about the anticipated commercialization strategy and expectations regarding the size of the market opportunities for product candidates to the forward-looking statements risk factor list.
- Newer filing (2026-08-11) adds language about the impact of government laws, regulations and tariffs to the forward-looking statements risk factor list.
- Newer filing (2026-08-11) updates employee count: states the Company had approximately 100 employees as of July 31, 2026.
- Newer filing (2026-08-11) adds a statement that the Company believes vidofludimus calcium positions it to pivot toward becoming a fully integrated commercial-stage multiple sclerosis company, and that it is building commercial, regulatory and organizational capabilities to support a potential launch in relapsing MS while continuing to advance the pipeline in progressive MS and other neurologic indications.
- Newer filing (2026-08-11) adds a description that the Company is focused on development and potential commercialization of orally administered, small molecule programs.
- Newer filing (2026-08-11) adds that an additional Phase 3 clinical trial of vidofludimus calcium in progressive MS is planned to be initiated.
- Newer filing (2026-08-11) references the development pipeline including earlier-stage programs IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases.
- Newer filing (2026-08-11) adds that if the ENSURE trials are positive, the Company intends to target submission of an NDA to the U.S. FDA in mid-2027, with potential U.S. regulatory approval in 2028.
- Newer filing (2026-08-11) adds detail to the CALLIPER results: states the primary percent brain volume change ('PBVC') endpoint was not met, and that exploratory imaging and clinical outcomes revealed consistent, directionally favorable signals.
- Newer filing (2026-08-11) adds CALLIPER data on reductions in slowly expanding lesions ('SEL') count over time.
- Newer filing (2026-08-11) adds that CALLIPER data confirmed favorable safety and tolerability profile 'similar to placebo'.
- Newer filing (2026-08-11) adds that initiation of a Phase 3 clinical trial of vidofludimus calcium in progressive MS is expected later in 2026.
- Newer filing (2026-08-11) adds a section describing the selection and status of the IMU-381 program, stating it is currently in preclinical testing.
- Newer filing (2026-08-11) updates total exposure to vidofludimus: states over 3,500 participants have been exposed in completed and ongoing clinical trials, with a maximum continuous exposure of more than 6.5 years.
- Removed:
- Older filing (2026-05-13) included a description of IMU-856 as targeted to regenerate bowel epithelium and restore intestinal barrier function, potentially applicable in gastrointestinal diseases such as celiac disease, IBD, and GvHD, which is not identically present in the newer excerpt (the newer text ends mid-sentence at 'IMU-856 is an o').
- Older filing (2026-05-13) included a description of the IMU-381 program as comprising next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases leveraging the Nurr1 platform; the newer excerpt describes the IMU-381 program differently and states it is currently in preclinical testing.
- Older filing (2026-05-13) included a detailed description of IMU-856 as an orally available and systemically acting small molecule modulator targeting SIRT6, and its mechanism of action; the newer excerpt is truncated and does not contain this equivalent text.
- Older filing (2026-05-13) included detailed Phase 1b clinical trial data for IMU-856 in celiac disease patients; the newer excerpt is truncated and does not contain this equivalent text.
- Older filing (2026-05-13) stated approximately 95 employees as of April 30, 2026; newer filing updates this figure.
- Older filing (2026-05-13) described the Company as pursuing clinical development of programs addressing serious chronic inflammatory and autoimmune diseases; the newer filing replaces this characterization with neurologic diseases language.
- Reworded:
- Newer filing (2026-08-11) changes 'We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases' to 'We are focused on development and potential commercialization of orally administered, small molecule programs with unique features intended to directly address the unmet needs of patients with neurologic and autoimmune diseases'.
- Newer filing (2026-08-11) changes 'relapsing multiple sclerosis ("RMS")' references to 'relapsing MS' (e.g., 'Phase 3 clinical development for patients with relapsing MS').
- Newer filing (2026-08-11) changes 'relapsing-remitting multiple sclerosis ("RRMS")' to 'relapsing-remitting MS' and 'progressive multiple sclerosis ("PMS")' to 'progressive MS' in the description of Phase 2 clinical trial activity.
- Newer filing (2026-08-11) changes 'our three product candidates' to 'our product candidates' in the sentence introducing the summary table.
- Newer filing (2026-08-11) changes 'Our most advanced drug candidate' to 'Our lead development candidate' when introducing vidofludimus calcium.
- Newer filing (2026-08-11) changes 'adult patients with active RMS' to 'adult patients with active relapsing MS' in the ENSURE enrollment description.
- Newer filing (2026-08-11) changes '30 mg daily doses' to 'a 30 mg daily dose' in the ENSURE randomization description.
- Newer filing (2026-08-11) changes the CALLIPER results description. The older filing stated the trial showed 'substantial and medically relevant reductions in 24-week confirmed disability worsening' and 'substantial and statistically significant data regarding 24-week confirmed disability improvement'; the newer filing states 'the primary percent brain volume change endpoint was not met' and describes 'substantial and medically relevant numerical reductions in 24-week confirmed disability worsening' and 'consistent increases in 24-week confirmed disability improvement'.
- Newer filing (2026-08-11) changes 'has already been exposed to more than 3,400 human subjects and patients in either of the drug's formulations' to 'Over 3,500 participants have been exposed... with a maximum continuous exposure of more than 6.5 years'.
- Newer filing (2026-08-11) changes 'targeted to regenerate bowel epithelium' description in older text to a truncated description beginning 'IMU-856 is an o' (though this appears due to excerpt truncation).
- Notes:
- The newer filing excerpt ends mid-sentence at 'IMU-856 is an o', so comparisons involving text after that point are limited to what is present in the excerpt and may reflect truncation of the source text rather than actual removal from the filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for IMUX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding IMUX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 203,679
- Reported value $3,130,546
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IMUX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IMUX had 2,075,709 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
IMUX had 15.2% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.56 days to cover at the same settlement.
- Reported short interest (shares) 2,075,709
- Short interest (% of shares outstanding) 15.2%
- Prior settlement (shares) 1,794,772
- Reported change 15.65%
- Days to cover (reported) 4.56
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Novartis (NVS)
- Sanofi (SNY)
- Bristol Myers Squibb (BMY)
- Roche (RHHBY)
- Merck KGaA (MKGAF)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IMUX vs…
Immunic, Inc. is found in…
Frequently asked questions
What does Immunic, Inc. (IMUX) do?
Immunic is a late-stage biotechnology company focused on developing oral, small-molecule therapies for neurologic and autoimmune diseases. Its primary focus is its lead candidate, vidofludimus calcium (IMU-838), which is in late-stage clinical development for the treatment of relapsing and progressive forms of multiple sclerosis. The company also maintains a pipeline of earlier-stage programs targeting neurodegenerative and inflammatory conditions.
What sector is Immunic, Inc. (IMUX) in?
Immunic, Inc. (IMUX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Immunic, Inc.'s (IMUX) competitors?
Notable peers of Immunic, Inc. (IMUX) include Biogen, Novartis, Sanofi, Bristol Myers Squibb and Roche. This peer set is informational only — not financial advice.
Is Immunic, Inc. (IMUX) overbought or oversold right now?
Immunic, Inc. (IMUX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMUX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.